Biosimilars – Another Option for Patients with Crohn’s Disease and Ulcerative Colitis

Treatment options for inflammatory bowel disease (IBD) have advanced significantly over the past few decades, particularly with the introduction of biologic therapies starting in 1998. Biologics like infliximab (Remicade®), adalimumab (Humira®), vedolizumab (Entyvio®), and ustekinumab (Stelara®) have changed IBD management, offering many patients improved quality of life and better control of their disease.

While biologics have been game-changers for many, they often come at a high cost. To address this issue, the FDA created an approval path for biosimilars—near-identical copies of existing biologic drugs that the FDA has already approved.  

Biosimilars are designed to be equally effective while being less expensive than the reference biologics, with potential to improve access to these critical treatments for patients. 
 

Biosimilars undergo rigorous FDA testing and approval processes. A number of studies have shown that biosimilars are just as safe and effective as the reference biologics. A recent podcast manuscript written by a Crohn’s disease patient advocate and a gastroenterologist highlights several studies that compare the use of biosimilars and reference biologics to treat patients with Crohn’s disease.

Patients currently stable on their biologic therapy or those considering starting on a biosimilar would understandably have questions. Fortunately, the answers are available.

The Crohn’s & Colitis Foundation offers numerous resources about biosimilars for patients and caregivers, including introductory materials, explanatory videos, and answers to common questions about biosimilars. Specialists at our IBD Help Center are also available to give personalized support to patients who are considering their various treatment options.
 

As more biosimilars enter the market, it’s important to stay informed and have open discussions with your healthcare provider to make the best decisions for your individual care and treatment plan. Click here to read and listen to this informative conversation in this podcast manuscript on biologics and biosimilars in the treatment of Crohn’s disease.

Thank you to our supporter: